Ipratropium/Salbutamol Cipla (Salbutamol, Ipratropium Bromide Monohydrate)

Ipratropium bromide blocks muscarinic receptors on airway smooth muscle, preventing acetylcholine‑induced constriction. Salbutamol activates β2‑adrenergic receptors, causing smooth‑muscle relaxation. The simultaneous inhibition of bronchoconstriction and promotion of bronchodilation produces a synergistic effect that improves airflow in obstructive airway conditions.

The dosage of Ipratropium/Salbutamol Cipla is determined by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. The prescriber will specify the number of inhalations, frequency, and duration appropriate for each individual case.

Safety data for Ipratropium/Salbutamol Cipla during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Pregnant or nursing patients should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the team will respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with monotherapy agents such as salbutamol alone or ipratropium alone, the combination provides additive bronchodilation, often resulting in faster symptom relief and improved lung function. This dual mechanism can be advantageous for patients who require both rapid and sustained airway opening, reducing the need for multiple separate inhalers.

Store Ipratropium/Salbutamol Cipla at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use to maintain potency.

The product is delivered by inhalation, typically using a nebulizer or a metered‑dose inhaler as directed by the prescriber. The patient should inhale slowly and deeply, hold the breath for a few seconds if possible, and then exhale. Proper technique ensures optimal drug deposition in the lungs.

Serious adverse events include paradoxical bronchospasm (worsening of breathing difficulty), severe allergic reactions such as angioedema or anaphylaxis, and cardiac arrhythmias, especially in patients with underlying heart disease. Any sudden worsening of symptoms or signs of an allergic reaction should prompt immediate medical attention.

The medication should be avoided in individuals with known hypersensitivity to ipratropium, salbutamol, or any excipients in the formulation. Caution is also advised for patients with severe narrow‑angle glaucoma, uncontrolled cardiovascular disease, or those taking certain interacting medications without close monitoring.